Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus

doi:10.5493/wjem.v5.i2.110

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8661)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

386

WORD

460

HTML

4930

Figures (1-4)

154

Tables (1-1)

159

Sum=6089

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1262

Download

1310

Sum=2572

May 20, 2015 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Exp Med. May 20, 2015; 5(2): 110-119
Published online May 20, 2015. doi: 10.5493/wjem.v5.i2.110

Full Size Figure Download Figure

Figure 4 Asymmetric dimethylarginine was significantly higher in diabetic cardiovascular disease development group than in diabetic cardiovascular disease non-development group.

Citation: Konya H, Miuchi M, Satani K, Matsutani S, Yano Y, Tsunoda T, Ikawa T, Matsuo T, Ochi F, Kusunoki Y, Tokuda M, Katsuno T, Hamaguchi T, Miyagawa JI, Namba M. Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus. World J Exp Med 2015; 5(2): 110-119
URL: https://www.wjgnet.com/2220-315X/full/v5/i2/110.htm
DOI: https://dx.doi.org/10.5493/wjem.v5.i2.110